177 related articles for article (PubMed ID: 28235701)
1. Design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine derivatives as mTOR inhibitors.
Mao B; Gao S; Weng Y; Zhang L; Zhang L
Eur J Med Chem; 2017 Mar; 129():135-150. PubMed ID: 28235701
[TBL] [Abstract][Full Text] [Related]
2. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
[TBL] [Abstract][Full Text] [Related]
3. Design of new disubstituted imidazo[1,2-
Elie J; Feizbakhsh O; Desban N; Josselin B; Baratte B; Bescond A; Duez J; Fant X; Bach S; Marie D; Place M; Ben Salah S; Chartier A; Berteina-Raboin S; Chaikuad A; Knapp S; Carles F; Bonnet P; Buron F; Routier S; Ruchaud S
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1840-1853. PubMed ID: 33040634
[TBL] [Abstract][Full Text] [Related]
4. Function-oriented synthesis of Imidazo[1,2-a]pyrazine and Imidazo[1,2-b]pyridazine derivatives as potent PI3K/mTOR dual inhibitors.
Li C; Han Y; Wang Z; Yu Y; Wang C; Ren Z; Guo Y; Zhu T; Li X; Dong S; Ma M
Eur J Med Chem; 2023 Feb; 247():115030. PubMed ID: 36586298
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors.
Zhu W; Sun C; Xu S; Wu C; Wu J; Xu M; Zhao H; Chen L; Zeng W; Zheng P
Bioorg Med Chem; 2014 Dec; 22(24):6746-54. PubMed ID: 25468038
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of Pyridazine Containing Compounds with Promising Anticancer Activity.
Elmeligie S; Ahmed EM; Abuel-Maaty SM; Zaitone SA; Mikhail DS
Chem Pharm Bull (Tokyo); 2017; 65(3):236-247. PubMed ID: 28250345
[TBL] [Abstract][Full Text] [Related]
8. Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor.
Bendjeddou LZ; Loaëc N; Villiers B; Prina E; Späth GF; Galons H; Meijer L; Oumata N
Eur J Med Chem; 2017 Jan; 125():696-709. PubMed ID: 27721154
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives.
Abdel-Maksoud MS; Kim MR; El-Gamal MI; Gamal El-Din MM; Tae J; Choi HS; Lee KT; Yoo KH; Oh CH
Eur J Med Chem; 2015 May; 95():453-63. PubMed ID: 25841200
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of imidazo[1,2-b]pyridazine derivatives having a benzamide unit as novel VEGFR2 kinase inhibitors.
Miyamoto N; Oguro Y; Takagi T; Iwata H; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2012 Dec; 20(24):7051-8. PubMed ID: 23123015
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors.
Zhang L; Bu T; Bao X; Liang T; Ge Y; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2017 Aug; 27(15):3395-3398. PubMed ID: 28633896
[TBL] [Abstract][Full Text] [Related]
12. Development of pyridazine derivatives as potential EGFR inhibitors and apoptosis inducers: Design, synthesis, anticancer evaluation, and molecular modeling studies.
Ahmed MF; Santali EY; Mohi El-Deen EM; Naguib IA; El-Haggar R
Bioorg Chem; 2021 Jan; 106():104473. PubMed ID: 33243490
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics.
Oguro Y; Cary DR; Miyamoto N; Tawada M; Iwata H; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Aug; 21(15):4714-29. PubMed ID: 23755884
[TBL] [Abstract][Full Text] [Related]
14. Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer.
Wu J; Wei T; Tang Q; Weng B; Li W; Jiang X; Ding T; Li X; Liang G; Cai Y; Ji J
BMC Cancer; 2015 Apr; 15():276. PubMed ID: 25880284
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity.
Liu Y; Xia Q; Fang L
Bioorg Med Chem; 2018 Aug; 26(14):3992-4000. PubMed ID: 29945756
[TBL] [Abstract][Full Text] [Related]
16. Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities.
Jaballah MY; Serya RAT; Saad N; Khojah SM; Ahmed M; Barakat K; Abouzid KAM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1573-1589. PubMed ID: 31852269
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and Structure-Activity Relationships of Novel Diaryl Urea Derivatives as Potential EGFR Inhibitors.
Jiang N; Bu Y; Wang Y; Nie M; Zhang D; Zhai X
Molecules; 2016 Nov; 21(11):. PubMed ID: 27869742
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives.
El-Gamal MI; Abdel-Maksoud MS; Gamal El-Din MM; Shin JS; Lee KT; Yoo KH; Oh CH
Anticancer Agents Med Chem; 2017; 17(1):75-84. PubMed ID: 27334850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
